Sadaf Elahi, MD
Nephrology · Lagrange, ILNPI 1124071147
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 67.3% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $5,074 and has fallen 94.4% since, to $282 in 2025.
Across 77 payments — averaging $101.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- Bayer$2K
- Vifor Pharma, Inc.$273
- Amgen$140
- Fresenius USA Marketing, Inc.$132
- Boehringer Ingelheim$87
- plus $354 from 12 others
Across 67 payments — averaging $7092.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$238K
- AstraZeneca$160K
- Eli Lilly$53K
- Boehringer Ingelheim$24K
- Boehringer Ingelheim International GmbH$302
What the payments were for
- Consulting fees$4,28455%
- Travel & lodging$1,43018%
- Food & beverage$2,10427%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 16 | $5,285 |
| Bayer | 15 | $1,579 |
| Vifor Pharma, Inc. | 11 | $273 |
| Amgen | 7 | $140 |
| Fresenius USA Marketing, Inc. | 6 | $132 |
| Boehringer Ingelheim | 3 | $87 |
| Calliditas Therapeutics US Inc. | 2 | $61 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Ardelyx, Inc. | 2 | $47 |
| Travere Therapeutics, Inc. | 4 | $46 |
| Novartis | 2 | $31 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Insulet Corporation | 1 | $19 |
| Novo Nordisk | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Strongbridge US Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,849 in reported general payments places this provider in the 85th percentile of 524 nephrology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Thiola EcTiopronin | 12 | $95,419 |
| FarxigaDapagliflozin Propanediol | 111 | $67,234 |
| JardianceEmpagliflozin | 60 | $52,377 |
| LokelmaSodium Zirconium Cyclosilicate | 50 | $35,605 |
| VeltassaPatiromer Calcium Sorbitex | 30 | $31,376 |
| Cinacalcet Hcl | 38 | $18,078 |
| Sevelamer Carbonate | 31 | $6,652 |
| Torsemide | 231 | $3,852 |
| Spironolactone | 197 | $2,548 |
| Eplerenone | 12 | $1,634 |
| Telmisartan | 44 | $1,228 |
| Potassium Chloride | 59 | $1,053 |
| Nifedipine ErNifedipine | 30 | $1,012 |
| Bumetanide | 14 | $742 |
| Losartan Potassium | 87 | $705 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $5,285 | $102,839161 claims |
| Boehringer IngelheimJardiance | $87 | $52,37760 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 524 nephrology providers in Illinois.
Other nephrology in Lagrange
- Myles WolfChicago$2.1M
- Mohammed AhmedBolingbrook$1.1M
- Anis RaufHinsdale$453K
- Juan LermaEvergreen Park$351K
- Stuart SpragueEvanston$337K
- Suneel UdaniHinsdale$336K
- Susan QuagginChicago$262K
- Nicole StankusChicago$235K
- Omaima DeganiGurnee$184K
- Merry DownerSpringfield$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.